News

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.

Shares of this Zacks Rank #3 (Hold) company have risen 41.9% year to date compared with the industry’s 5% growth. The S&P 500 Index has also increased 10.9% in the same time frame.

Glaukos, with a market capitalization of $5.68 billion, is a leading ophthalmic medical technology and pharmaceutical company. It projects earnings growth of 0.4% for 2024, followed by 42% growth in 2025, and expects to maintain its strong performance in terms of revenues as well.

Image Source: Zacks Investment Research

The company has a negative four-quarter average earnings surprise of 4.74%.

Key Catalysts

In 2023, Glaukos witnessed sales returning to growth after experiencing a downturn in 2022. This positive shift can be attributed to a more favorable macroeconomic climate and the introduction of a series of new products in recent quarters. The company anticipates sustained robust demand in its international Glaucoma and Corneal Health product lines to support its top-line growth in 2024.

The commercial launch of the iStent infinite in 2023 has provided a significant lift to the U.S. glaucoma franchise, positioning it as a key growth catalyst in the forthcoming quarters. The company's optimistic revenue projections for 2024 indicate a positive trajectory.

Meanwhile, the new local coverage determinations proposed in June 2023 are likely to remove certain ophthalmic goniotomy and canaloplasty procedures from coverage. This is also expected to have a positive impact on the iStent business in 2024.

Over recent quarters, GKOS has launched a suite of products, including iPrime, iAccess and iStent, which have been instrumental in boosting the company's revenues. In December, the company achieved a milestone by securing FDA approval for its latest product, iDose TR, to lower intraocular pressure in individuals with ocular hypertension or open-angle glaucoma.

These innovations are expected to continue to bolster Glaukos' growth trajectory into 2024. Earlier this month, the company received a permanent Healthcare Common Procedure Coding System J-code from the U.S. Centers for Medicare and Medicaid Services, which should drive patient access in the United States. This is because it will likely accelerate the billing and physician reimbursement procedures.

In May, Glaukos announced first-quarter 2024 results. The company’s net sales were $85.6 million, up 16% year over year. Revenues for 2024 are estimated to be in the range of $357-$365 million, implying a year-over-year improvement of 13.4-16%.

What’s Hurting GKOS?

Although Glaukos has a promising pipeline, it has faced setbacks in terms of clinical development or regulatory activities. Any potential clinical or regulatory setback can have an adverse impact on the company’s share price, thereby hurting investors’ wealth.

The FDA denied approval to a pre-market approval application for the ab-externo device for glaucoma, MicroShunt. The company is currently evaluating alternate regulatory pathways for approval, and its commercial launch in the United States remains uncertain.

Moreover, Glaukos currently relies on a limited number of third-party suppliers, in some cases sole suppliers, to supply components for the iStent, the iStent inject models and other pipeline products. If one or more of these suppliers cease to provide the company with sufficient quantities of components or drugs in a timely manner or on acceptable terms, it would have to seek alternative sources of supply.

Glaukos' production of the iStent, iStent inject models and other products in development depends on a select group of third-party suppliers, occasionally exclusive ones. If any of these suppliers fails to deliver the necessary components or drugs in a timely manner or on acceptable terms, Glaukos would be compelled to find other suppliers to maintain its production line.

Estimate Trend

The bottom-line estimate for GKOS is pegged at a loss of $2.26 per share for 2024. The Zacks Consensus Estimate for 2024 revenues is pinned at $362.3 million, indicating growth of 15.1% from the top line recorded in 2023.

Glaukos Corporation Price

Stocks to Consider

Some better-ranked stocks in the broader medical space that have announced quarterly results are Align Technology, Inc. ALGN, Ecolab ECL and Boston Scientific Corporation BSX.

Align Technology, currently carrying a Zacks Rank of 2 (Buy), reported first-quarter 2024 adjusted earnings per share (EPS) of $2.14, which beat the Zacks Consensus Estimate by 8.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Revenues of $997.4 million outpaced the consensus mark by 2.6%.

Align Technology, currently carrying a Zacks Rank of 2, reported first-quarter 2024 adjusted EPS of $2.14, which beat the Zacks Consensus Estimate by 8.1%. Revenues of $997.4 million outpaced the consensus mark by 2.6%. Align Technology’s shares have lost 6.1% year to date against the industry’s 0.5% growth.

Ecolab has a long-term growth rate of 14.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.30%.

Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%. Ecolab’s shares have risen 17.1% year to date against the industry’s 19.9% decline.

Boston Scientific reported first-quarter 2024 adjusted EPS of 56 cents, which beat the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. The company currently carries a Zacks Rank #2.

Boston Scientific has a long-term estimated growth rate of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.5%. Boston Scientific’s shares have rallied 30.8% year to date compared with the industry’s 2.7% growth.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Boston Scientific Corporation (BSX) : Free Stock Analysis Report

Ecolab Inc. (ECL) : Free Stock Analysis Report

Align Technology, Inc. (ALGN) : Free Stock Analysis Report

Glaukos Corporation (GKOS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.